Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of 2-dose nonavalent human papillomavirus vaccine in women aged 21-26 years
TCTR20261016003Phase 2Not yet recruiting
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- Nov 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Faculty of Medicine, Chulalongkorn University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on TCTR20261016003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261016003.